Harriet Kluger, MD
Historically, patients with melanoma who develop brain metastases have been excluded from clinical trials, according to Harriet Kluger, MD.
on Melanoma. In an interview during the meeting, Kluger, professor of medicine, associate cancer center director for Education and Training, Yale Cancer Center, discussed the lack of clinical trial inclusion as well as promising regimens coming down the pike.
OncLive®: Please provide an overview of your talk.
: The topic is systemic therapy for brain metastases in melanoma. By systemic therapy, we mean therapy that goes in via mouth or intravenously, as opposed to local therapies in the form of radiation, surgery, or stereotactic radiosurgery. Until recently, systemic therapy was not actually one of the modalities that we would first think of to treat brain metastases. The reason is that stereotactic radiosurgery is actually very effective and can control approximately 90% of the metastases long term.
... to read the full story